News | March 16, 2026
First patient dosed in trial of novel drug targeting limb-threatening artery disease
The trial will enroll up to 42 patients in Finland across four cohorts
The trial will enroll up to 42 patients in Finland across four cohorts
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process
The protections extend through at least 2035, with the potential for further extensions
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
Subscribe To Our Newsletter & Stay Updated
